The invention relates to the use of anti-IL-6 antibodies or antibody fragments containing a specific epitopic specificity to treat conditions involving elevated Il-6. In some embodiments the anti-IL-6 antibodies contain specific CDRs.

Claims

27 · 3 independent · depth 3

27 granted claims

›1.independentA method of treating a disease or condition associated with elevated human interleukin-6 (IL-6), comprising administering a therapeutically effective …+14

›2.↳ 1The method of claim 1, wherein the variable light chain polypeptide and the variable heavy chain polypeptide each possess at least 95% sequence identi…d2

›3.↳ 1The method of claim 1, wherein the variable light chain polypeptide and the variable heavy chain polypeptide each possess at least 97% sequence identi…d2

›4.↳ 1The method of claim 1, wherein the antibody or antibody fragment has an in vivo half-life of at least about 22 days in a healthy human subject.d2

›5.↳ 1The method of claim 1, wherein the antibody or antibody fragment has a binding affinity (Kd) for IL-6 of less than about 50 picomolar, or a rate of di…d2

›6.↳ 1The method of claim 1, wherein the antibody or antibody fragment contains an Fc region that has been modified to alter effector function, half-life, p…d2

›7.↳ 1The method of claim 1, wherein the antibody is selected from a humanized, single chain, or chimeric antibody and the antibody fragment is selected fro…d2

›8.↳ 1The method of claim 1, wherein the therapeutically effective amount is between about 0.1 and 20 mg/kg of body weight of recipient subject.d2

›9.↳ 1The method of claim 1, wherein said anti-IL-6 antibody or fragment inhibits the binding of IL-6 to gp130.d2

›10.↳ 1The method of claim 1, wherein said anti-IL-6 antibody or fragment inhibits the binding of IL-6 to IL-6R1.d2

›11.↳ 1The method of claim 1, wherein said anti-IL-6 antibody or fragment inhibits the binding of IL-6 to both gp 130 and IL-6R1.d2

›12.↳ 1The method of claim 1, wherein said anti-IL-6 antibody or fragment neutralizes IL-6 in vivo.d2

›13.↳ 1The method of claim 1, wherein the anti-IL-6 antibody or antibody fragment comprises a human constant region.d2+2

›16.independentA method of treating a disease or condition associated with elevated human interleukin-6 (IL-6), comprising administering a therapeutically effective …+10

›17.↳ 16The method of claim 16, wherein said anti-IL-6 antibody or fragment inhibits the binding of IL-6 to gp 130.d2

›18.↳ 16The method of claim 16, wherein said anti-IL-6 antibody or fragment inhibits the binding of IL-6 to IL-6R1.d2

›19.↳ 16The method of claim 16, wherein said anti-IL-6 antibody or fragment inhibits the binding of IL-6 to both gp 130 and IL-6R1.d2

›20.↳ 16The method of claim 16, wherein said anti-IL-6 antibody or fragment neutralizes IL-6 in vivo.d2

›21.↳ 16The method of claim 16, wherein said anti-IL-6 antibody or antibody fragment has a binding affinity (Kd) for IL-6 of less than about 50 picomolar, or …d2

›22.↳ 16The method of claim 16, wherein the anti-IL-6 antibody or antibody fragment contains an Fc region that has been modified to alter effector function, h…d2

›23.↳ 16The method of claim 16, wherein the anti-IL-6â€”antibody or fragment is selected from a human, humanized, single chain, or chimeric antibody and the a…d2

›24.↳ 16The method of claim 16, wherein the anti-IL-6 antibody or antibody fragment comprises a human constant region.d2+2

›27.independentA method of treating a disease or condition associated with elevated human interleukin-6 (IL-6), comprising administering a therapeutically effective …

Classifications

16 codes

IPC · International Patent Classification

Section A — Human necessities

A61K39/395
A61K49/00
A61K39/00
A61K51/10

Section C — Chemistry; metallurgy

C07K16/24
C12N15/63
C12P21/08

USPC · US Patent Classification

424/133.1424/178.1530/391.7530/387.9530/388.15530/388.1530/387.3424/130.1424/158.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

5.0 y

1,834 days filing → grant

Office actions

after a restriction

Responses

4 RCE

Examiner

Bridget E Bunner

art unit 1647 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 318 back · 1 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

25 Nov 2008

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 61117811	25 Nov 2008
related publication	US 20100150829 A1	17 Jun 2010

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.